...
首页> 外文期刊>BMC Cancer >Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews
【24h】

Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews

机译:在中期和短期下死亡的高风险高危患者中系统性肿瘤治疗患者的疗效:系统评价概述

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Esophageal and gastric cancers are a significant public health problem worldwide, with most patients presenting with advanced-stage disease and, consequently, poor prognosis. Systemic oncological treatments (SOT) have been widely used over more conservative approaches, such as supportive care. Nevertheless, its effectiveness in this scenario is not sufficiently clear. This paper provides an overview of systematic reviews that assessed the effectiveness of SOT compared with the best supportive care (BSC) or placebo in patients with advanced esophageal or gastric cancers in an end-of-life context. We searched MEDLINE, EMBASE, The Cochrane Library, Epistemonikos, and PROSPERO for eligible systematic reviews (SRs) published from 2008 onwards. The primary outcomes were overall survival (OS), progression-free survival (PFS), functional status, and toxicity. Two authors assessed eligibility and extracted data independently. We evaluated the methodological quality of included SRs using the AMSTAR-2 tool and the overlap of primary studies (corrected covered area, CCA). Also, we performed a de novo meta-analysis with data reported for each primary study when it was possible. We assessed the certainty of evidence using the GRADE approach. We identified 16 SRs (19 included trials) for inclusion within this overview. Most reviews had a critically low methodological quality, and there was a very high overlap of primary studies. It is uncertain whether SOT improves OS and PFS over more conservative approaches due to the very low certainty of evidence. The evidence is very uncertain about the effectiveness of SOT for advanced esophageal or gastric cancers. High-quality SRs and further randomized clinical trials that include a thorough assessment of patient-centered outcomes are needed. Open Science Framework, https://doi.org/10.17605/OSF.IO/7CHX6 .
机译:食管和胃癌是全球性的重要公共卫生问题,大多数患者患有晚期疾病,并因此差不多,预后差。全身肿瘤治疗(SOT)已被广泛应用于更多保守的方法,例如支持性护理。然而,在这种情况下的有效性并不充分清晰。本文概述了系统评价,评估了SOT的有效性与在生命结束环境中具有晚期食管或胃癌的患者的最佳支持性护理(BSC)或安慰剂。我们搜索了Medline,Embase,Cochrane图书馆,Epistemonikos和Prospero以获得2008年从2008年发布的符合条件的系统评论(SRS)。主要结果是整体存活(OS),无进展生存(PFS),功能状态和毒性。两位作者评估了资格和独立提取数据。我们使用AMSTAR-2工具和初级研究重叠评估包括SRS的方法论质量(矫正区域,CCA)。此外,我们在可能的情况下,通过报告的数据进行了DE Novo Meta分析。我们评估了使用年级方法的证据的确定性。我们确定了16个SRS(包括19项试验)纳入本概述。大多数评论具有危重的方法质量,初级研究具有很高的重叠。由于证据肯定的肯定,不确定SOT是否改善了OS和PFS在更保守的方法上。证据对SOT对晚期食管或胃癌的有效性非常不确定。需要高质量的SRS和进一步随机临床试验,包括彻底评估患者以患者为中心的结果。开放科学框架,https://doi.org/10.17605/osf.io/7chx6。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号